A large, preprint study found those who took a Paxlovid pill regimen within five days of testing positive for COVID-19 had lower chances — specifically a 26% reduced risk — of developing some long COVID symptoms.
New findings suggest Pfizer’s COVID-19 pill Paxlovid may offer protection against lingering coronavirus symptoms — otherwise known as long COVID — regardless of vaccination status.as “new, returning, or ongoing” health issues experienced at least four weeks after a COVID-19 infection. It can be the cause of lasting brain fog, fatigue, heart palpitations and more as it affects many parts of the body.
The work examined U.S. Department of Veterans Affairs records of 56,340 people who tested positive for COVID-19 between March and June. But based on the Veterans Affairs study, which acknowledges there is no proven long COVID medication, Paxlovid may be another way to reduce the risk of developing it, Topol said.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
New VA study finds Paxlovid may cut the risk of long COVIDFor those at high risk, Pfizer's antiviral drug helps stave off severe COVID-19. Now research suggests it may also reduce their chances of long COVID.
Consulte Mais informação »
Paxlovid reduces risk of long Covid, Veterans Affairs study finds | CNNPaxlovid, the antiviral pill that reduces the risk of hospitalization and death from Covid-19, also reduces the risk of long Covid, according to a new study by researchers at the US Department of Veterans Affairs.
Consulte Mais informação »
Paxlovid reduces long-COVID risk, VA study findsPfizer's antiviral pill Paxlovid can reduce the risk of long COVID symptoms like organ damage, per a pre-print study released by the Dept. of Veterans Affairs.
Consulte Mais informação »
Paxlovid Cuts the Risk of Long COVID: VA StudyPaxlovid, the antiviral drug designed to reduce the risk of death and hospitalization from COVID-19, may also help cut the chances a person will develop long COVID, a study by the U.S. Department of Veterans Affairs shows.
Consulte Mais informação »
Paxlovid Cuts the Risk of Long COVID: VA StudyPaxlovid, the antiviral drug designed to reduce the risk of death and hospitalization from COVID-19, may also help cut the chances a person will develop long COVID, a study by the U.S. Department of Veterans Affairs shows.
Consulte Mais informação »